NovaBridge Biosciences (NBP) Hisse Özeti

NBP temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Analistler hisse senedi fiyatının 352% oranında artacağı konusunda hemfikir

Risk Analizi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Geliri 1 milyon ABD dolarından az ( $0 )

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 20.1% oranında düşmesi öngörülüyor

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

NBP Community Fair Values

Create Narrative

See what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

NovaBridge Biosciences Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti NovaBridge Biosciences
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.77
52 Haftanın En Yüksek Seviyesi	US$6.79
52 Haftanın En Düşük Seviyesi	US$0.98
Beta	1.56
1 Aylık Değişim	-31.40%
3 Aylık Değişim	-46.20%
1 Yıllık Değişim	78.79%
3 Yıllık Değişim	-43.09%
5 Yıllık Değişim	-97.82%
Halka arzdan bu yana değişim	-85.84%

Son Haberler & Güncellemeler

Recent updates

Analiz Makalesi • Dec 31

NovaBridge Biosciences (NASDAQ:NBP) Shares Could Be 41% Below Their Intrinsic Value Estimate

Key Insights Using the 2 Stage Free Cash Flow to Equity, NovaBridge Biosciences fair value estimate is US$6.72...

Seeking Alpha • Oct 14

I-Mab Biopharma Stock: Caution Warranted After Huge Surge

Summary I-Mab stock has surged in 2025 on strong early data for lead asset givastomig in gastric cancer, showing an 83% ORR. Givastomig's results outperformed approved therapies and competitors, fueling optimism amid a large metastatic gastric cancer market and high unmet need. IMAB raised $61.2 million in an August 2025 secondary, securing a cash runway through 2028, with positive analyst sentiment but modest long-term sales projections. Read the full article on Seeking Alpha

Seeking Alpha • Feb 18

I-Mab: Trading Below Net Cash With Multiple Upside Options

Summary I-Mab Biopharma has signed an agreement to divest its assets and business operations in China, becoming a US-based biotech company. The divesting will provide I-Mab with a healthy balance sheet, over $400 million in cash, and the potential to receive up to $80 million in cash consideration from its divested China operation. I-Mab's core assets will consist of three global Immuno-Oncology programs, including uliledlimab, which has shown promising Phase 2 NSCLC clinical trial data. Read the full article on Seeking Alpha

Analiz Makalesi • Feb 08

We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Seeking Alpha • Sep 27

I-Mab: Another CD47 Inhibitor Biotech With Great Potential

Summary Clearance from China was received to initiate a phase 3 registrational study using Lemzoparlimab for high-risk MDS patients; trial initiation is expected in Q4 of 2022. Results from phase 2 studies using uliledlimab for the treatment of patients with non-small cell lung cancer are expected in Q4 of 2022. Two other products in the pipeline nearing BLAs in China are felzartamab for multiple myeloma and eftansomatropin alfa for growth hormone deficiency. The global Myelodysplastic Syndrome market is expected to reach $3.26 billion in 2022. I-Mab (IMAB) is a great speculative biotech play to look into. The reason why I state that is because it has a drug known as Lemzoparlimab. The goal is to initiate a phase 3 study using this drug in combination with azacitidine for the treatment of 1st-line myelodysplastic syndrome ((MDS)). The biotech had a great end of phase 2 meeting with Chinese authorities and received the go ahead to initiate a phase 3 study for this program. This late-stage study is expected to be initiated in Q4 of 2022. In addition, the company is also exploring a few other indications with the use of Lemzoparlimab. It has developed a partnership with AbbVie (ABBV) to develop new CD47 antibodies. If such a partnership makes it all the way through all the milestones, then I-Mab would be entitled to receive up to $1.295 billion in milestone payments. The biotech is also in the process of initiating another phase 3 registrational trial as well. This involves the use of its differentiated CD73 antibody uliledlimab being developed to treat patients with non-small cell lung cancer ((NSCLC)). It also has plans to initiate a phase 3 study in the United States targeting other cancer types, however, it hopes to do so through other drugs besides PD-1 inhibitors within the next 12 months. It will also make available results from the ongoing phase 2 study of uliledlimab for the treatment of patients with NSCLC by the end of 2022. The main thing you probably want to know is, what is its intended goal? It believes it could have 5 clinical-stage assets with at least three Biologic Licensing Applications (BLAs) within the next 3 years. Then, it has a bispecific antibody known as TJ-CD4B, which is being developed to treat patients with various types of solid tumors. This drug is currently being explored in a phase 1 study. One key thing to note is that I-Mab is exploring partnership opportunities for uliledlimab and TJ-CD4B, which could also create shareholder value as well. CD47 Inhibitor With Proof Of Concept Already Established The first program to go over involves the use of Lemzoparlimab for the treatment of patients with Myelodysplastic Syndrome. Myelodysplastic Syndrome ((MDS)) involves a group of cancers that keep your blood stem cells from maturing into healthy blood cells. However, MDS can also cause other problems as well, ranging from developing Acute Myeloid Leukemia ((AML)) or anemia (lack of healthy red blood cells to carry oxygen), frequent infections, and bleeding episodes which may not stop. Healthy red blood cells are made in the soft spongy area known as the bone marrow. If such production doesn't work, then red blood cells die in the bone marrow, or if they reach out to parts of your body they die off. When red blood cells die in the bone marrow, there is no room for the healthy red blood cells to exist. This effect leads to serious problems, which is why MDS needs to be taken care of. The global Myelodysplastic Syndrome market is expected to reach $3.26 billion in 2022 and grow at about 9.3% CAGR thereafter until 2030. There are several symptoms that these patients experience as well, which are as follows: You are tired/weak Skin becomes pale Bleed more often Frequent infections Frequent fevers. The goal for I-Mab is to advance Lemzoparlimab to a phase 3 study in treating newly diagnosed higher-risk MDS patients in Q4 of 2022. Of course, it already received authorization from the CDE and NMPA (Chinese authority agencies) to begin such a study. It expects to initiate this phase 3 registrational study before the end of this year, likely Q4 of 2022. The main reason why I'm talking about this program is because it is the furthest along. If a phase 3 study starts by the end of this year for Lemzoparlimab for newly diagnosed MDS patients, then results should be out within a few years. If the trial meets the primary endpoint at completion, then I-Mab holds the potential to have the first CD47 approved in China. That's because, according to talks with Chinese Authorities, this is a registrational trial, which is capable of having a BLA filed should the primary endpoint be met. Thus far, it is a pretty good product in terms of treating patients with hematological malignancies (blood cancers). That is evident by the clinical data achieved to date. About 90 patients with newly diagnosed MDS or acute myeloid leukemia (AML) have received 30 mg/kg Lemzoparlimab in combination with azacitidine (chemotherapy). It was revealed that even without any type of priming dose given to about 50 MDS patients, combination treatment of Lemzoparlimab was very safe/tolerable. It was shown that in terms of MDS patients, there was a >80% objective response rate ((ORR)). With magrolimab and Azacitidine, the combination is comparable to being slightly below this 80% ORR number. Gilead Sciences (GILD) owns magrolimab (CD47 inhibitor) now after buying Forty Seven Inc awhile back. However, I-Mab released updated results at the European Society for Medical Oncology ((ESMO)) Congress 2022 on September 10, 2022 with an oral presentation. For MDS patients receiving a dose of Lemzoparlimab at 3 months, the ORR was 80.6%, and then over 6 months of dosing the ORR rose to 86.7%. The complete response rate in the most recent update was said to be 40%. With this data on hand, it can now push forward to going after high risk MDS patients in the phase 3 study it just received authorization for. Financials According to the 6-K SEC Filing, I-Mab has a cash position of $586 million on hand. It believes that with the current cash on hand, that it could fund its operations for more than 3 years. One thing to keep in mind for this speculative biotech name is that, while its financials are in good order, there is an overhang of an HFCAA delisting. This is not guaranteed, but a possibility because of legislation act holding foreign companies accountable. I believe this is huge risk - as such, I thought it was important to mention this. It should be good on cash for the time being, therefore, I don't see it needing to raise cash in the near-term. I believe what could be possible is if it chooses to raise cash after receiving regulatory approvals in China for one of the BLAs expected in the coming years. Risks To Business There are several risk factors to consider before investing in this biotech. The biggest risk factor would be the overhang of the HFCAA delisting noted above. However, I-Mab states that it has the situation under control by providing shareholders a road map and value to what it intends to do so that it won't be delisted. It believes it can mitigate delisting risks under the HFCAA based on specific steps it has taken in the last 6 months. Despite taking this action, there is still no assurance that it won't face this risk of delisting. It hopes that its current plan of the Statement of Protocol, or a possible contingency plan of changing its auditor should it need to, will accomplish this. The second risk would be with respect to the initiation of the phase 3 registration study, which is using Lemzoparlimab for the treatment of high risk MDS patients. It will take a few years to run this study, and if the primary endpoint is not met, then I-Mab will not be able to file a BLA for approval of this drug in China.

Seeking Alpha • Sep 13

I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome

Chinese biotech I-Mab (NASDAQ:IMAB) on Tuesday said it got local regulatory approval to start a phase 3 trial evaluating its antibody lemzoparlimab in combination with cancer drug azacitidine for the treatment of myelodysplastic syndrome (MDS). MDS is a group of cancers caused due to blood cells that are poorly formed or don't work properly. The approval to start the trial follows a successful completion of an end-of-phase 2 meeting with the Center for Drug Evaluation of China's National Medical Products Administration, IMAB said in a statement. The meeting was supported by results from a phase 2 trial assessing lemzoparlimab in combination with azacitidine for the treatment of patients with newly diagnosed higher-risk MS, IMAB said. The company said it is on track to initiate the late-stage study as planned. U.S.-listed shares of IMAB -4.8% at $5.31 in morning trading.

Seeking Alpha • Aug 30

I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M

I-Mab Biopharma press release (NASDAQ:IMAB): 1H Non-GAAP EPADS of -$1.54. Revenue of $7.74M (+181.5% Y/Y).

Seeking Alpha • Aug 23

I-Mab and senior executives may buy $40M worth of shares; stock up 10%

I-Mab (NASDAQ:IMAB) and senior management using their own personal funds may purchase up to $40M worth of the company's American Depository Shares on the open market. The buys are part of a share repurchase program previously authorized by the company's board. Shares are up 10% in Tuesday morning trading. See why Seeking Alpha contributor Chris Lacoursiere is bullish on I-Mab (IMAB).

Analiz Makalesi • Aug 20

Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts

Today is shaping up negative for I-Mab ( NASDAQ:IMAB ) shareholders, with the analysts delivering a substantial...

Seeking Alpha • Jul 22

I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China

I-Mab (NASDAQ:IMAB) said the first patient in China had been treated with its TJ-CD4B in a Phase 1 international multi-center clinical trial for patients with solid tumors, including gastric cancer, gastroesophageal junction carcinoma. TJ-CD4B binds to Claudin 18.2-expressing cancer cells and co-stimulatory molecule 4-1BB on T cells to exert a tumor-killing effect. In March, the U.S. Food and Drug Administration granted Orphan Drug Designation to TJ-CD4B for the treatment of gastric cancer including cancer of gastroesophageal junction.

Seeking Alpha • Jun 23

I-Mab Valuation Offers A Biotech Investment Opportunity

The biotech indices have fallen considerably. Many biotechs are trading with negative enterprise values despite unprecedented innovation in the biotech industry. I-Mab is headed for commercialization with enough cash to carry then into 2025 with multiple products hitting the market. I-Mab shares appear significantly undervalued.

Analiz Makalesi • May 24

Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Seeking Alpha • May 06

I-Mab Shaken By Management Moves, Merger Talk And Delisting Threat

There’s no shortage of market-moving news these days about up-and-coming cancer drug maker I-Mab, whose stock is getting pulled every which way as a result. The U.S.-China dispute element was in the headlines this week, when I-Mab’s name was added to a U.S. Securities and Exchange Commission list of 88 Chinese firms that could face potential delisting. According to its 2021 annual report, the company has enough capital to fund its operations through 2025, with $671 million in cash combined with expected milestone payments.

Analiz Makalesi • Apr 01

Bearish: Analysts Just Cut Their I-Mab (NASDAQ:IMAB) Revenue and EPS estimates

The analysts covering I-Mab ( NASDAQ:IMAB ) delivered a dose of negativity to shareholders today, by making a...

Seeking Alpha • Jan 03

I-Mab Founder Retakes Reins In Latest Shakeup Ahead Of Commercialization Phase

Four-year company veteran and CEO Joan Shen to depart I-Mab as chairman and founder Zang Jingwu gets set to resume the role. Analysts upbeat as company earmarks 2023 for regulatory approval of key drugs and launch of production facility. Despite that positive outlook, the company’s shares have gone on a rollercoaster ride since listing at $14 in January 2020.

Seeking Alpha • Oct 14

I-Mab Gets Boost From Latest Industry Signals On New Cancer Treatment

I-Mab's shares surged up to 15% on positive results from a peer developing a similar new type of cancer treatment, though they later gave back most of those gains. Company has plenty of cash on hand and could soon get more as it seeks a deal to commercialize the drug, uliledlimab, with a U.S. or European partner. Despite I-Mab's recent stock price volatility, many are still quite bullish on the company.

Hissedar Getirileri

	NBP	US Biotechs	US Pazar
7D	-2.7%	1.2%	1.0%
1Y	78.8%	34.9%	28.7%

Getiri vs. Endüstri: NBP geçen yıl % 34.9 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: NBP geçen yıl % 28.7 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is NBP's price volatile compared to industry and market?
NBP volatility
NBP Average Weekly Movement	9.7%
Biotechs Industry Average Movement	11.0%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.4%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: NBP son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: NBP 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 17% dan 10% a düştü.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2014	30	Sean Fu	novabridge.com

Bir biyoteknoloji şirketi olan NovaBridge Biosciences, Amerika Birleşik Devletleri'nde kanser tedavisi için immüno-onkoloji ajanlarının araştırılması ve geliştirilmesiyle ilgilenmektedir. Şirket, Onkoloji ve Oftalmoloji olmak üzere iki segmentte faaliyet göstermektedir. Ürün hattı, mide kanseri ve diğer CLDN18.2-pozitif gastrointestinal malignitelerin tedavisi için nivolumab ve kemoterapi ile kombinasyon halinde faz 2 klinik çalışmasında olan potansiyel bir CLDN18.2 bispesifik antikor olan givastomig'i içermektedir; birinci basamak mide kanserinde nivolumab ve kemoterapi ile kombinasyon halinde faz 1b klinik çalışması.

NovaBridge Biosciences Temel Bilgiler Özeti

NovaBridge Biosciences'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
NBP temel i̇stati̇sti̇kler
Piyasa değeri	US$205.85m
Kazançlar(TTM)	-US$88.34m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-2.3x

F/K Oranı

NBP aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
NBP gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$88.34m
Kazançlar	-US$88.34m

Son Raporlanan Kazançlar

Dec 31, 2025

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.76
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

NBP uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/22 09:16
Gün Sonu Hisse Fiyatı	2026/05/22 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

NovaBridge Biosciences 17 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Bo Li	BofA Global Research
Kumaraguru Raja	Brookline Capital Markets
Ziyu He	China International Capital Corporation Limited

NovaBridge Biosciences (NBP) Hisse Özeti

Ödüller

Risk Analizi

NovaBridge Biosciences Rakipler

Humacyte

Keros Therapeutics

Black Diamond Therapeutics

Century Therapeutics

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Less than half of directors are independent

Novabridge Biosciences Appoints Mark Hagler as President and Chief Commercial Officer

NovaBridge Biosciences Announces Productive FDA Type B Meeting On Potential Accelerated Approval Pathway For Givastomig In Gastric Cancer

Novabridge Biosciences Announces Positive Results from Vis-101 Phase 2A Wet Amd Study

NovaBridge Biosciences Appoints Emmett T. Cunningham, Jr. as Vice Chairman of the Board and Member of the Research and Development Committee

NovaBridge Biosciences Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer

Recent updates

Less than half of directors are independent

Novabridge Biosciences Appoints Mark Hagler as President and Chief Commercial Officer

NovaBridge Biosciences Announces Productive FDA Type B Meeting On Potential Accelerated Approval Pathway For Givastomig In Gastric Cancer

Novabridge Biosciences Announces Positive Results from Vis-101 Phase 2A Wet Amd Study

NovaBridge Biosciences Appoints Emmett T. Cunningham, Jr. as Vice Chairman of the Board and Member of the Research and Development Committee

NovaBridge Biosciences Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer

NovaBridge Biosciences Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer

NovaBridge Biosciences (NASDAQ:NBP) Shares Could Be 41% Below Their Intrinsic Value Estimate

NovaBridge Biosciences Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO

Novabridge Biosciences Announces Presentation of Ragistomig Expanded Phase 1 Data At Esmo-Io

Novabridge Biosciences Appoints Ian Woo to Its Board of Directors

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025

I-Mab Biopharma Stock: Caution Warranted After Huge Surge

I-Mab Announces Acceleration of Givastomig Investment

I-Mab Announces Board Changes

I-Mab Completes Enrollment in Planned Phase 1B Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers

I-Mab has completed a Follow-on Equity Offering in the amount of $65.000001 million.

I-Mab Inc. Announces Data Based on the Results of the Dose Escalation Part of A Phase 1B Study Evaluating the Givastomig Combination as First Line Therapy

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers At Esmo Gi 2025

I-Mab to Report Q1, 2025 Results on May 15, 2025

I-Mab Announces Accelerated Givastomig Phase 1B Study Progress

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

I-Mab Appoints Sean (Xi-Yong) Fu as Chief Executive Officer

I-Mab to Report Q3, 2024 Results on Nov 14, 2024

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

I-Mab to Report First Half, 2024 Results on Aug 28, 2024

I-Mab Announces Board and Committee Changes

I-Mab Appoints Phillip Dennis as Chief Medical Officer

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates upgraded to CN¥12.72 loss

I-Mab: Trading Below Net Cash With Multiple Upside Options

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-Mab Announces Board Changes , Effective February 10, 2024

Member of Scientific Advisory Board notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Price target decreased by 17% to US$21.56

Chief Legal Officer notifies of intention to sell stock

I-Mab and Hi-Bio Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation for Felzartamab, an Investigational Cd38 Antibody, for the Treatment of Primary Memorbranous Nephropathy (PMN)

I-Mab Announces Phase 1 Data of Givastomig at Esmo 2023

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1Bb Bispecific Antibody Tj-L14b Abl503

New minor risk - Share price stability

Consensus revenue estimates fall by 15%

Consensus revenue estimates fall by 78%

Price target decreased by 19% to US$24.47

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab to Report First Half, 2023 Results on Aug 17, 2023

Member of Scientific Advisory Board notifies of intention to sell stock

I-Mab Announces the Appointment of Raj Kannan as Member of the Board of Directors

TRACON Pharmaceuticals, Inc. Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma

Price target increased by 8.5% to US$27.65

Interim CFO notifies of intention to sell stock

Price target increased by 7.2% to US$27.30

Price target decreased by 11% to US$29.81

Price target decreased by 7.7% to US$33.57

We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate

Member of Scientific Advisory Board notifies of intention to sell stock

Price target decreased to US$36.38

Less than half of directors are independent

First half 2022 earnings: EPS and revenues miss analyst expectations

I-Mab: Another CD47 Inhibitor Biotech With Great Potential

I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome